EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Establishing Screening Programs for Presymptomatic Type 1 Diabetes: Practical Guidance for Diabetes Care Providers

Steven B Leichter iD, Jamie L Felton iD, Cristy Geno Rasmussen iD, Patrick Rizzuto iD, Natalie Bellini iD, Osagie Ebekozien iD, Rifka Schulman-Rosenbaum iD

The Journal of Clinical Endocrinology & Metabolism · 15.07.2025 · 110 (8) · 2371-2382

DOI: 10.1210/clinem/dgaf194 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 02.04.2025. Verfasst von Steven B Leichter und 6 weiteren Autor:innen. Beteiligte Einrichtung: Piedmont Endocrinology Columbus, Columbus, GA 31904, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Autoantibodies, Mass Screening, Diagnostic Screening Programs. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Ann Todd, Sanofi US.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 diabetes (T1D) is an autoimmune disease with 2 presymptomatic stages (stages 1 and 2) that precede its clinical onset (stage 3). The presymptomatic stages of T1D are characterized by circulating autoantibodies that can be reliably detected by autoantibody screening panels. Identifying people in the presymptomatic stages of T1D can allow for monitoring and prevention of diabetic ketoacidosis. A disease-modifying therapy that has been shown to delay onset of stage 3 T1D is now also available for individuals with stage 2 disease, highlighting the importance of early detection. This intervention may delay the onset of stage 3 T1D. Updated guidance and protocols are needed to integrate autoantibody screening into standard practice. This report provides guidance for endocrinology providers on establishing clinical autoantibody screening programs within their practices, institutions, healthcare networks, and/or communities. Key steps include nominating a champion for the program, building a team to implement screening, and motivating other providers to participate. Implementation of screening requires standardizing several steps in the screening process, including communicating with individuals at risk, integrating screening into existing workflows, and streamlining logistics such as ordering and coding for autoantibody panels. Providers must have a plan to interpret and communicate results and to ensure that individuals may be appropriately followed in the future. Here, common barriers to screening are addressed, and practical solutions to facilitate the adoption and success of screening initiatives are offered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1AutoantibodiesMass ScreeningDiagnostic Screening ProgramsHumansPractice Guidelines as TopicEarly DiagnosisHealth Personnel

Stichwörter der Autor:innen

autoantibodyautoimmuneendocrinologyscreeningtype 1 diabetes

Substanzen

Autoantibodies

Autor:innen und Institutionen

  • Piedmont Endocrinology Columbus, Columbus, GA 31904, USA.
  • Department of Internal Medicine, Mercer University School of Medicine, Columbus, GA 31901, USA.
  • Department of Pediatrics, Herman B Wells Center for Pediatric Research, Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
  • Implementation Science Department, Medstar Health Research Institute, Columbia, MD 21044, USA.
  • Division of Endocrinology, Department of Pediatrics, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.
  • Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.

ORCID-Profile: Steven B Leichter, Jamie L Felton, Cristy Geno Rasmussen, Patrick Rizzuto, Natalie Bellini, Osagie Ebekozien, Rifka Schulman-Rosenbaum

Förderung

  • NIDDK NIH HHS
  • Ann Todd
  • Sanofi US

Zitieren

APA

Leichter, S. B., Felton, J. L., Geno Rasmussen, C., Rizzuto, P., Bellini, N., Ebekozien, O., & Schulman-Rosenbaum, R. (2025). Establishing Screening Programs for Presymptomatic Type 1 Diabetes: Practical Guidance for Diabetes Care Providers. The Journal of Clinical Endocrinology & Metabolism, 110(8), 2371-2382. https://doi.org/10.1210/clinem/dgaf194

Vancouver

Leichter SB, Felton JL, Geno Rasmussen C, Rizzuto P, Bellini N, Ebekozien O, et al. Establishing Screening Programs for Presymptomatic Type 1 Diabetes: Practical Guidance for Diabetes Care Providers. The Journal of Clinical Endocrinology & Metabolism. 2025;110(8):2371-2382. doi:10.1210/clinem/dgaf194

BibTeX
@article{Leichter2025,
  author = {Leichter, Steven B and Felton, Jamie L and Geno Rasmussen, Cristy and Rizzuto, Patrick and Bellini, Natalie and Ebekozien, Osagie and Schulman-Rosenbaum, Rifka},
  title = {Establishing Screening Programs for Presymptomatic Type 1 Diabetes: Practical Guidance for Diabetes Care Providers},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {8},
  pages = {2371--2382},
  doi = {10.1210/clinem/dgaf194}
}
Kostenlos starten →